Dose-Ranging Safety, Tolerability, and Efficacy Study of AZD2373 in Participants With APOL1-Mediated Kidney Disease
← catalyst calendarNCT06824987 · readout in 375 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
136estimated
Sites
89
Countries
United Kingdom, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-03-05 | actual | When the study began enrolling |
| Primary completion | 2027-08-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-08-30 | estimated | The whole study's end, after follow-up |
| First posted | 2025-02-13 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-25 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- APOL1-Mediated Kidney Disease
Interventions
- Combination product: AZD2373-Arm 1
- Combination product: AZD2373-Arm 2
- Combination product: Placebo
- Device: APOL1 Genotyping Clinical Trial Assay
Primary outcome
what the primary-completion date above is the date OFRelative change in Urine Albumin-Creatinine Ratio (UACR)
measured From Baseline at Week 30
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed